Ascletis Pharma Inc. has submitted two Investigational New Drug applications to the United States Food and Drug Administration for ASC36, a once-monthly peptide amylin receptor agonist, and ASC36_35 FDC, a once-monthly fixed-dose injection combining ASC36 with the GLP-1 and GIP receptor agonist ASC35. The filings move both obesity candidates towards possible Phase I testing and expand the Hong Kong-listed biotechnology firm’s effort to build a portfolio around longer-acting weight-management therapies.
Why does a monthly amylin programme matter in an obesity market dominated by incretin drugs?
The strategic significance of ASC36 extends beyond the addition of another experimental obesity drug. Most of the current commercial market has been built around glucagon-like peptide-1 receptor agonism, either alone or combined with glucose-dependent insulinotropic polypeptide receptor activity. Ascletis is attempting to add amylin receptor agonism as a separate biological lever while extending the interval between injections from weekly to monthly and potentially, in the future, quarterly administration.
Amylin is a pancreatic hormone associated with satiety, meal termination and the regulation of food intake. This makes the pathway attractive as both an alternative to incretin therapy and a potential partner for incretin-based drugs. A successful amylin medicine could broaden treatment choices for people who do not obtain the desired balance of efficacy and tolerability from existing therapies. It could also support combination regimens designed to deliver deeper weight reduction without relying exclusively on higher incretin doses.
The challenge is that amylin is no longer an uncontested opportunity. Eli Lilly and Company has moved the selective amylin receptor agonist eloralintide into late-stage development following Phase II weight reductions of up to 20.1% at 48 weeks. Zealand Pharma A/S and Roche Holding AG are advancing petrelintide as both a standalone treatment and as part of a fixed-dose combination with the GLP-1 and GIP receptor agonist CT-388. Novo Nordisk A/S has already submitted its weekly cagrilintide and semaglutide combination to the United States Food and Drug Administration.
Ascletis is therefore entering a competitive field in which clinical-stage rivals already possess human efficacy, tolerability and pharmacokinetic data. Monthly dosing could offer meaningful differentiation, but convenience will not compensate for weaker weight reduction, difficult dose escalation or persistent adverse effects. ASC36 must demonstrate that its extended dosing interval reflects durable therapeutic exposure rather than simply prolonged presence of the drug in circulation.
Why must the ASC36 animal comparisons be treated as promising signals rather than clinical proof?
ASC36 produced approximately 91% greater relative body-weight reduction than petrelintide and approximately 32% greater relative reduction than eloralintide in separate head-to-head studies involving diet-induced obese rats. The ASC36_35 fixed-dose combination produced approximately 51% greater relative body-weight reduction than co-administered eloralintide and tirzepatide in another rat study.
These comparisons give Ascletis a basis for selecting doses, prioritising candidates and supporting clinical entry. Head-to-head animal experiments may be more informative than comparisons assembled from unrelated studies because the drugs can be tested under common conditions. They can also help developers explore differences in potency, exposure and treatment duration before exposing human participants to a new molecule.
They cannot, however, establish that ASC36 will outperform petrelintide or eloralintide in people. Obesity drug performance is affected by receptor biology, baseline weight, sex, dietary conditions, dose escalation, treatment duration and the relationship between drug exposure and adverse events. A large relative difference in a rodent model may translate into a smaller clinical advantage, no meaningful difference or an entirely different tolerability profile.
The comparison with eloralintide and tirzepatide requires particular caution because the competing regimen already has human clinical experience, while ASC36_35 FDC remains preclinical. Human obesity treatment is also measured using absolute and placebo-adjusted weight reduction, discontinuation rates, categorical weight-loss thresholds and changes in cardiometabolic risk factors. Relative superiority in animals does not answer those questions.
The credible near-term objective is not to prove that ASC36 is already better than advanced competitors. It is to show that the preclinical findings justify human development and that pharmacologically active exposures can be maintained for a full month without creating unacceptable safety or tolerability problems.
How could the ASC36_35 fixed-dose injection improve adherence while restricting dose flexibility?
ASC36_35 FDC combines amylin receptor agonism with GLP-1 and GIP receptor activity in one monthly injection. The concept is designed to address two important competitive variables at the same time: the magnitude of weight reduction and the burden of repeated administration.
A person receiving separate weekly amylin and incretin injections could require eight injections during a four-week period. A single monthly co-formulation would reduce that theoretical burden to one injection. Lower injection frequency could simplify chronic treatment, reduce prescription-management complexity and improve the appeal of combination therapy for patients who might otherwise prefer a simpler monotherapy.
The biological rationale is also credible. Amylin and incretin pathways influence appetite, satiety, gastric function and metabolic control through partly distinct mechanisms. Combining them may permit broader appetite regulation or stronger weight reduction than either component can provide alone. The approach resembles the wider industry shift from single-receptor medicines towards dual-pathway and triple-pathway obesity treatments.
Fixed dosing creates a different set of constraints. The ideal ASC36 dose may not align with the ideal ASC35 dose for every patient. Someone who tolerates the amylin component but develops incretin-related gastrointestinal symptoms may require a lower ASC35 exposure without reducing ASC36. A fixed combination cannot provide that flexibility unless Ascletis develops several dose ratios or a staged treatment strategy.
This issue becomes more significant during dose escalation. Obesity medicines are commonly introduced gradually to manage nausea, vomiting, diarrhoea, fatigue and other treatment-emergent effects. A monthly depot formulation could make rapid dose correction difficult because exposure may continue after an injection has been administered. Ascletis will need to determine whether escalation can be sufficiently controlled when two active peptides are released from the same depot over an extended period.
Later development will also need to demonstrate that both components make a meaningful contribution to the combination. Evidence that ASC36_35 FDC outperforms placebo may not be enough. Regulators are likely to require a clear understanding of how the combination compares with ASC36 alone, ASC35 alone and potentially other relevant treatment arms.
What does the FDA IND review need to resolve before human dosing can begin?
An Investigational New Drug submission is an important regulatory transition, but it is not equivalent to clinical clearance or product approval. The United States Food and Drug Administration generally has 30 calendar days after receiving an initial application to review whether the proposed investigation presents an unreasonable risk to participants. A study can proceed after the review period if the application is not placed on clinical hold, or earlier if the regulator explicitly allows development to begin.
The immediate regulatory focus is therefore safety and the suitability of the proposed first-in-human protocols. Ascletis must support its starting doses, dose-escalation plan, nonclinical toxicology package, manufacturing controls and monitoring procedures. For ASC36_35 FDC, the review must also address the combined exposure to two investigational peptides and whether the proposed trial can distinguish risks associated with each component.
ASC35 has already received clearance for a United States Phase I trial as a once-monthly GLP-1 and GIP receptor agonist. That milestone may reduce some uncertainty around one part of the combination because regulators have already reviewed an ASC35 development package. It does not automatically validate the ASC36_35 co-formulation, which introduces a second active molecule, a new exposure profile and additional formulation considerations.
A clinical hold could be triggered by questions about toxicology, starting-dose justification, participant monitoring, manufacturing consistency or protocol design. Even without a hold, regulators may request additional information or modifications. The next meaningful milestone is therefore confirmation that both programmes can enter Phase I testing under acceptable protocols.
Which Phase I findings will determine whether monthly dosing becomes a real competitive advantage?
Pharmacokinetics will be the first major test of the ASC36 thesis. In non-human primates, the self-assembling lipid depot formulation of ASC36 produced an observed half-life approximately six times longer than eloralintide. This supported the proposed once-monthly to once-quarterly dosing concept, while the ASC36_35 formulation produced extended observed half-lives for both active components.
Human data must establish whether the depot releases ASC36 and ASC35 predictably across participants. Investigators will need to examine peak concentrations, time to peak exposure, effective half-life, accumulation after repeated dosing and the relationship between exposure and pharmacodynamic activity. A long half-life is valuable only when the resulting concentration profile remains within a useful therapeutic range.
Safety findings may be even more decisive. Early trials will need to monitor gastrointestinal events, fatigue, injection-site reactions, changes in vital signs, laboratory abnormalities and any evidence of immune responses to the peptides or formulation. The durability of exposure means that an adverse reaction may not be rapidly reversible simply by stopping daily or weekly dosing.
For the combination, the exposure curves of ASC36 and ASC35 must remain sufficiently coordinated. If one component is released faster or persists longer, the effective ratio could change during the month. That could alter efficacy or tolerability even when the amount placed in the injection is fixed.
Early changes in body weight, appetite, calorie intake and metabolic markers may provide pharmacodynamic evidence, but Phase I studies are usually too small and short to establish comparative weight-loss efficacy. The most informative outcome would be a dose range that produces sustained biological activity with acceptable tolerability and no need for impractically slow escalation.
Can Ascletis manufacture a stable monthly depot consistently at commercial scale?
The disclosed formulations use Ascletis’ self-assembling lipid depot technology, which is intended to extend peptide exposure after subcutaneous administration. ASC36 and ASC36_35 FDC have demonstrated chemical and physical stability at neutral pH without aggregation or precipitation associated with fibrillation.
That stability is relevant because peptide co-formulation can be difficult. Interactions between active molecules may affect solubility, potency, release behaviour and shelf life. Avoiding visible aggregation in development studies is an encouraging starting point, especially for a product intended to combine two peptides in one injection.
Commercial readiness requires considerably more evidence. Ascletis must show that manufacturing batches produce consistent depot properties, impurity profiles, potency and release kinetics. Injection volume, viscosity, needle compatibility, storage requirements and the reproducibility of drug release could all influence whether the formulation is practical for large-scale use.
Long-acting products can also create demanding quality-control requirements because small manufacturing changes may affect the duration or pattern of exposure. A formulation that works reliably in laboratory and early clinical supplies may require further optimisation before it can be produced economically and distributed across multiple markets.
The platform could become strategically valuable if it works across ASC35, ASC36 and future combinations. Repeated clinical validation would allow Ascletis to position the technology as more than a formulation used for one drug. Failure to reproduce exposure or tolerability across programmes would weaken the broader platform argument.
What will determine whether ASC36 becomes a differentiated obesity asset rather than another early pipeline entrant?
The two IND submissions show that Ascletis is executing a broad obesity-development strategy rather than relying on a single candidate. The portfolio includes oral and injectable GLP-1 receptor agonists, dual GLP-1 and GIP receptor agonists, amylin medicines and several fixed-dose combinations. This creates opportunities to address initial weight reduction, long-term maintenance and different patient tolerability profiles.
Breadth also increases capital and execution demands. Each programme requires toxicology, clinical operations, manufacturing development and regulatory engagement. Advancing multiple related assets may strengthen partnering leverage, but it can also spread resources across candidates before the strongest clinical profile has been identified.
ASC36 will become genuinely differentiated only if human studies confirm three features simultaneously: competitive efficacy, acceptable tolerability and a dosing interval meaningfully longer than weekly alternatives. ASC36_35 FDC faces an additional requirement because the convenience of one monthly injection must be balanced against the reduced flexibility of a fixed combination.
The most credible interpretation is that the filings give Ascletis a potentially valuable entry into the emerging amylin segment, but they do not yet establish competitive superiority. The next stage is less about whether the animal data look impressive and more about whether the lipid depot can deliver predictable, safe and clinically active exposure in people. That human evidence will determine whether monthly administration becomes a defensible advantage or remains an attractive preclinical promise.
